South Korean pharmaceutical company Yuhan has decided to end its collaboration with Janssen Biotech in developing a new targeted anticancer drug due to the success of its current treatment, Lazertinib. The termination of their partnership includes discontinuing the development of a fourth-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer patients with specific mutations. Yuhan's official stated that the combination therapy of Lazertinib and Janssen's Amivantamab has shown reduced resistance mutations, making the need for a fourth-generation treatment unnecessary. In addition to ending the collaboration, milestone payments for the project have been reduced from $1.25 billion to $950 million. However, the upfront payment of $50 million and the development of Lazertinib and Amivantamab combination therapy will continue unaffected. Yuhan will retain the rights to Lazertinib in Korea, while Janssen will have rights to the combination therapy. Despite the partnership's conclusion, Yuhan remains committed to further developing treatments for Lazertinib within the country. Furthermore, Yuhan has also secured an $80.9 million contract with Gilead Sciences to supply active pharmaceutical ingredients for HIV treatments until September 30, 2025, representing a significant portion of the company's revenue.